Arcus Biosciences raises $250M through share sale priced at $17.50
Arcus Biosciences priced 14.29 million shares at $17.50 each, for expected gross proceeds of $250 million. Settlement is slated for October 23, 2026.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Arcus Biosciences (RCUS) set the offering price for 14,285,715 common shares at $17.50 apiece. Expected gross proceeds are $250.0 million, according to TradingView, which cited a press release distributed by BusinessWire.
Underwriters received a 30-day option to buy up to 2,142,857 more shares. All of the shares being sold are primary, meaning the money goes to the company and the number of shares outstanding will rise. Settlement is expected on October 23, 2026, subject to customary conditions.
why it matters
For the market this is a typical dilutive offering: a larger share count can pressure the stock in the near term, but the capital extends the company's cash runway. Exercise of the option would enlarge the deal and add further dilution. The syndicate includes Jefferies, Leerink and TD Cowen, among others.
tags
instruments
sources
- Arcus Biosciences, Inc. (RCUS) Prices $250M Equity Offering — TradingView, 22 October 2026 at 02:53 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗